Amid a busy year and new lead­er­ship, Lon­za looks to build bio­con­ju­gates ca­pac­i­ty with Swiss ex­pan­sion set for 2022

The year 2020 has been busy for con­tract man­u­fac­tur­ers, a trend which is hold­ing strong as an un­prece­dent­ed 12 months draw to a close. Swiss CD­MO Lon­za, one of the biggest play­ers in the field and un­der the re­cent lead­er­ship of Roche vet Pierre-Alain Ruffieux, has been at the fore­front of that out­sourc­ing boom, and now it’s look­ing to keep on grow­ing for what could be an even busier fu­ture.

Buoyed by deals to pro­duce 1 bil­lion world­wide dos­es of Mod­er­na’s Covid-19 vac­cine, Lon­za an­nounced an ex­pan­sion Mon­day that will in­crease its pro­duc­tion ca­pac­i­ty 30% by the first half of 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.